本报讯 （记者刘欢）10月24日晚间，甘肃陇神戎发药业股份有限公司（以下简称"陇神戎发"）披露 2025年第三季度报告。前三季度，公司实现营业收入6.47亿元；归属于上市公司股东的净利润2702.94万 元，同比增长8.11%；归属于上市公司股东的扣除非经常性损益的净利润2871.34万元，同比增长 31.14%。 今年前三季度，在中药行业回暖的大背景下，陇神戎发凭借核心产品市场竞争力的不断提升和产业布局 的持续深化，实现经营业绩稳步增长，经营质量稳步提升。 （编辑 张伟） 今年以来，陇神戎发持续聚焦主业发展，不断优化市场销售布局，在进一步巩固核心产品元胡止痛滴 丸、宣肺止嗽合剂的市场占有率的同时，充分挖掘复方丹参片、七味温阳胶囊、鞣酸小檗碱膜等现有普 药产品市场潜力，加大销售渠道开发力度，取得了较好的市场反馈。此外，该公司持续推动大健康产品 市场销售上量，啡得乐植物饮料、黄芪当归饮、薄荷爽口片、枸杞原浆、肉苁蓉原浆等系列大健康产品 受到消费者的广泛关注和好评。 作为业绩增长的核心引擎，陇神戎发两大独家品种元胡止痛滴丸与宣肺止嗽合剂市场竞争力和品牌影响 力不断提升。元胡止痛滴丸作为无成瘾性的纯中药全科类止痛用 ...

陇神戎发(300534)于10月24日盘后披露2025年三季度报告，公司在前三季度展现出稳健的经营态势与业 绩增长动力。前三季度，公司实现营业收入6.47亿元，归母净利润达2702.94万元，同比增长8.11%；扣 非后归母净利润为2871.34万元，同比增幅达31.14%。在中药行业整体回暖的背景下，陇神戎发凭借核 心产品市场竞争力的不断增强与产业布局的持续深化，推动经营质量稳步提升，展现出良好的发展韧 性。 在巩固药品主业的同时，公司积极拓展大健康产品板块，啡得乐植物饮料、黄芪当归饮、薄荷爽口片、 枸杞原浆、肉苁蓉原浆等系列产品受到消费者广泛关注与好评，市场开拓不断深入。通过多渠道开发与 市场精准触达，公司进一步提升了品牌综合竞争力。 作为国家高新技术企业、甘肃省首批战略性新兴产业骨干企业，并获评"专精特新"中小企业及创新型企 业，陇神戎发长期专注于中成药、原料药、保健食品、医药中间体、化学药品和医疗器械的研发、生产 与销售。公司坚持以主业为核心，不断优化销售网络与产品结构，夯实高质量发展基础。 展望四季度，公司表示将持续聚焦中药主业，持续强化市场开拓和科研开发工作，推动公司健康可持续 发展。（秦声） 业 ...

Core Viewpoint - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. reported a steady growth in revenue and net profit for the first half of 2025, demonstrating resilience amid a challenging economic environment [1][2]. Financial Performance - The company achieved an operating income of 496 million yuan and a net profit attributable to shareholders of 27.96 million yuan, representing a year-on-year increase of 27.48% [1]. - The net profit excluding non-recurring gains and losses was 30.49 million yuan, up 39.93% year-on-year [1]. Market Strategy - The company focused on enhancing its marketing efforts, particularly in promoting its major products, with the coverage of its flagship products reaching 2,858 hospitals for Yuanhu Zhiting Diban and 2,299 hospitals for Xuanfei Zhiso Heji, marking coverage increases to 19.39% and 15.56% respectively [2]. - Revenue from the droplet products grew by 31.22% year-on-year, contributing to overall performance improvement [2]. Project Development - The company completed the acquisition of 70% of the Gansu Pharmaceutical Group Technology Innovation Research Institute, enhancing its drug research and development capabilities [3]. - Upgrades to the production line for Xuanfei Zhiso Heji were completed, achieving compliance with GMP standards, which will boost production capacity [3]. - The construction of a production line for a new type of medical device is progressing, which is expected to create new business growth opportunities [3]. Research and Development - A technical center laboratory was established in collaboration with a subsidiary, improving the R&D infrastructure and facilitating the transition from laboratory to industrial production [4]. - Ongoing development of main products includes real-world studies for Xuanfei Zhiso Heji and Yuanhu Zhiting Diban, as well as collaborations with Lanzhou University for health food R&D [4]. Investor Returns and Social Responsibility - The company plans to distribute cash dividends of 0.2 yuan per 10 shares, totaling 6.07 million yuan [4]. - The company has been recognized for its commitment to green development and has made donations of 1 million yuan to support areas affected by recent natural disasters [4].

Group 1: Company Overview and Key Products - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. has two main products: Yuanhu Zhitong Diban and Xuanfei Zhike Heji, which are positioned as core offerings in the market [2][3] - Yuanhu Zhitong Diban is a unique product in China, included in the National Essential Medicines List, recognized for its effectiveness in treating various types of pain [2][3] - Xuanfei Zhike Heji is classified as a national-level new drug, suitable for cough relief, and has received multiple awards for its quality and effectiveness [3][4] Group 2: Product Development and Marketing Strategy - The company is focused on secondary development of major products and building technological barriers through various research projects [4][5] - Ongoing projects include clinical efficacy evaluations and production process improvements for Yuanhu Zhitong Diban and Xuanfei Zhike Heji [4][5] - A professional marketing platform is being developed to enhance brand influence and market share, targeting both hospitals and OTC markets [4][5] Group 3: Health Product Expansion - The company has launched several health products, including Huangqi Danggui capsules and plant-based beverages, with plans for further market promotion [5][6] - Future development will focus on health products that align with market demand, leveraging the parent company's advantages in the traditional Chinese medicine industry [5][6] Group 4: Industry Opportunities and Challenges - Recent government policies support the innovation and quality improvement of traditional Chinese medicine, creating a favorable environment for industry growth [6][7] - The aging population increases demand for chronic disease management and health maintenance, expanding market opportunities for traditional Chinese medicine products [6][7] - The company aims to enhance its competitive edge by improving product quality and increasing R&D investment in response to these opportunities [7]